INSMED INC Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
INSMED INC (INSM) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$267.07 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-19
- INSMED INC effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$267.07M.
- INSMED INC effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$191.11M.
- INSMED INC effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$156.87M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$267.07M 10-K · filed 2026-02-19 |
| 2024-12-31 | -$191.11M 10-K · filed 2026-02-19 |
| 2023-12-31 | -$156.87M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |